Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 2141-2149

  Wang, Liang ^a   Chi, Pei Dong ^a   Chen, Hao ^a   Xiang, Jin ^a   Xia, Zhong Jun ^a   Zhang, Yu Jing ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Extranodal natural killer T cell lymphoma; High density lipoprotein cholesterol; Inflammation; Lymphomagenesis; Prognosis

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; BETA 2 MICROGLOBULIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OXALIPLATIN; PREDNISONE; VINCRISTINE;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CHOLESTEROL BLOOD LEVEL; CONTINUOUS INFUSION; FEMALE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LIPID METABOLISM; LYMPHOMAGENESIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHOLESTEROL, HDL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, EXTRANODAL NK-T-CELL; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84898914186     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1284-z     Document Type: Article

References (38)

1. Chan JK, Quintanilla-Martinez L, Ferry JA, Peh S-C. Extranodal NK/T-cell lymphoma, nasal type. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 285-8.
2. Li YX, Liu QF, Fang H, Qi SN, Wang H, et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res. 2009;15:2905-12.
3. Guo Y, Lu JJ, Ma X, Wang B, Hong X, et al. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy. Oral Oncol. 2008;44:23-30.
4. Wu X, Li P, Zhao J, Yang X, Wang F, et al. A clinical study of 115 patients with extranodal natural killer/T-cell lymphoma, nasal type. Clin Oncol (R Coll Radiol). 2008;20:619-25.
5. Kim WS, Song SY, Ahn YC, Ko YH, Baek CH, et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol. 2001;12:349-52.
6. Wang B, Lu JJ, Ma X, Guo Y, Lu H, et al. Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T cell lymphoma of nasal cavity. Leuk Lymphoma. 2007;48:396-402.
7. Wang B, Li XQ, Ma X, Hong X, Lu H, et al. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008;83:795-9.
8. Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011;29(33):4410-6.
9. Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834-9.
10. Wang L, Wang ZH, Chen XQ, Li YJ, Wang KF, et al. First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma. Cancer. 2013;119:348-55.
11. Huang H, Lin Z, Lin X, Cai Q, Xia Z, et al. Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience. Leuk Lymphoma. 2011;52:1041-8.
12. Kim TM, Park YH, Lee SY, Kim JH, Kim DW, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood. 2005;106:3785-90.
13. Lee J, Suh C, Park YH, Ko YH, Bang SM, et al. Extranodal natural killer T-cell lymphoma, nasal type: a prognostic model from a retrospective multicenter study. J Clin Oncol. 2006;24:612-8.
14. Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients. Int J Hematol. 2012;96:617-23.
15. Kim HS, Kim KH, Kim KH, Chang MH, Ji SH, et al. Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. Leuk Lymphoma. 2009;50:757-63.
16. Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, et al. Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type. Blood. 2011;118:6018-22.
17. Li ZM, Zhu YJ, Sun J, Xia Y, Huang JJ, et al. Serum beta2-microglobin is a predictor of prognosis in patients with upper aerodigestive tract NK/T-cell lymphoma. Ann Hematol. 2012;91(8):1265-70.
18. Spiegel RJ, Schaefer EJ, Magrath IT, Edwards BK. Plasma lipid alterations in leukemia and lymphoma. Am J Med. 1982;72:775-82.
19. Blackman JD, Cabana VG, Mazzone T. The acute phase response and associated lipoprotein abnormalities accompanying lymphoma. J Intern Med. 1993;233:201-4.
20. Esteve E, Ricart W, Fernandez-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005;24:16-31.
21. Lim U, Gayles T, Katki HA, Stolzenberg-Solomon R, et al. Serum high-density lipoprotein cholesterol and risk of non-Hodgkin lymphoma. Cancer Res. 2007;67(11):5569-74.
22. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol. 1993;11:1573-82.
23. Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18:3633-42.
24. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.
25. Dessí S, Batetta B, Anchisi C, Pani P, Costelli P, et al. Cholesterol metabolism during the growth of a rat ascites hepatoma (Yoshida AH-130). Br J Cancer. 1992;66(5):787-93.
26. Breslow JL, Eisenberg S, Brinton EA. Metabolic determinants of low HDL-C levels. Ann N Y Acad Sci. 1993;676:157-62.
27. Dessì S, Batetta B, Spano O, Sanna F, Tonello M, et al. Clinical remission is associated with restoration of normal high-density lipoprotein cholesterol levels in children with malignancies. Clin Sci (Lond). 1995;89(5):505-10.
28. 31P NMR spectroscopy in clinical analysis of changes of serum phospholipids in leukemia, lymphoma and some other non-haematological cancers. Anticancer Res. 1996;16(3B):1587-94.
29. 31P MRS to the analysis of phospholipid changes in plasma of patients with acute leukemia. BiochemBiophys Acta Mol Cell Biol L. 2005;1737(1):11-5.
30. Kuliszkiewicz-Janus M, Małecki R, Mohamed AS. Lipid changes occurring in the course of hematological cancers. Cell Mol Biol Lett. 2008;13(3):465-74.
31. Kuliszkiewicz-Janus M, Baczyński S. Treatment-induced changes in 31P-MRS (magnetic resonance spectroscopy) spectra of sera from patients with acute leukemia. Biochim Biophys Acta. 1997;1360(1):71-83.
32. Mihou D, Katodritou E, Zervas K. Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model. Hematology. 2007;12(6):527-31.
33. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605-21.
34. Lin ZX, Bai B, Cai QC, Cai QQ, Wang XX, et al. High numbers of tumor-associated macrophages correlate with poor prognosis in patients with mature T- and natural killer cell lymphomas. Med Oncol. 2012;29(5):3522-8.
35. Zhang W, Wang L, Zhou D, Cui Q, Zhao D, et al. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma. 2011;52(1):46-52.
36. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, et al. The double jeopardy of HDL. Ann Med. 2005;37(3):173-8.
37. Tietge UJ, Maugeais C, Cain W, Rader DJ. Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA2. Am J Physiol Endocrinol Metab. 2003;285:E403-11.
38. Tamura T, Inagawa S, Hisakura K, Enomoto T, Ohkohchi N. Evaluation of serum high-density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. J Gastroenterol Hepatol. 2012;27:1635-40.